Search Results

Data Presented at the AVA Annual Scientific Meeting Shows Significantly Lower Complication and Failure Rates with Access Vascular’s HydroMID® Midline Catheter

Merit Medical Systems, Inc., a global leader of healthcare technology, announced US Food and Drug Administration 510 clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

Merit Medical Systems, Inc., a leading global manufacturer and marketer of healthcare technology, announced it has completed the acquisition of a portfolio of dialysis catheter products and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. for a total cash consideration of $100 million.

Access Vascular, Inc. announced findings from new data showing a reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters and midline catheters with AVI’s MIMIX® hydrophilic biomaterial compared with conventional catheters.

enVVeno Medical Corporation (NASFAQ:NVNO) (“enVVeno” or the “Company”) today announced that positive interim venous ulcer healing data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve will be presented today at the Society for Vascular Surgery 2024 Vascular Annual Meeting in Chicago.

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL.

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease, announced the closing of its $87 million Series B financing round.

Access Vascular, Inc. announced that the Infusion Nurses Society has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery.